European Cannabis Companies Race To The Nasdaq: $1B In Tax Break On The Horizon
Portfolio Pulse from Nicolás Jose Rodriguez
European cannabis companies are planning IPOs on Nasdaq, driven by potential regulatory changes in the US and Germany. Companies like Grow Group, Somai Pharmaceuticals, and Wellford Medical are eyeing Nasdaq listings. US companies Curaleaf and Trulieve could benefit from tax breaks if cannabis is rescheduled to Schedule III. IM Cannabis and InterCure are also poised for growth in the European market.
July 18, 2024 | 7:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Curaleaf could see a 92% increase in operating cash flow if cannabis is rescheduled to Schedule III, allowing for tax deductions on normal business expenses.
The rescheduling of cannabis to Schedule III would allow Curaleaf to deduct normal business expenses, significantly boosting cash flow and enabling growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 80
POSITIVE IMPACT
IM Cannabis is intensifying its focus on the German market following recent legalization, enhancing its supply chain with a new EU-GMP supplier.
IM Cannabis's strategic focus on the German market and supply chain enhancements position it well for growth in Europe.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 60
POSITIVE IMPACT
InterCure is poised to benefit from potential US rescheduling of cannabis and growing demand in Germany, leveraging its experience in Israel.
InterCure's experience in Israel and potential benefits from US rescheduling and German market demand position it for significant growth.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 65
POSITIVE IMPACT
Trulieve's operational efficiency positions it well for revenue growth from potential legislative changes, with significant tax savings expected.
Trulieve's operational efficiency and potential tax savings from rescheduling cannabis to Schedule III could lead to substantial revenue growth.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 70